Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.
719.4EUR
719.4EUR
În stoc
Număr Catalog 716-EP-158-96testsCategorieAfaceri și industrie > Știință și laboratorFurnizorACROBIOSYSTEMSGentaurDimensiune96testsTipsingle